title: Comparison of effects of losartan, irbesartan, and candesartan on flow-mediated brachial artery dilation and on inflammatory and thrombolytic markers in patients with systemic hypertension.
abstract: We administered placebo, losartan 100 mg/day, irbesartan 300 mg/day, and candesartan 16 mg/day during 2 months to 122 patients with mild to moderate hypertension. Compared with placebo, angiotensin II type-1 receptor blockers significantly improved the percent flow-mediated dilator response to hyperemia (p = 0.019 by analysis of variance [ANOVA]) and reduced plasma levels of malondialdehyde (p = 0.005 by ANOVA). However, only irbesartan and candesartan therapies significantly lowered plasma levels of plasminogen activator inhibitor type-1 antigen (p <0.001 by ANOVA) with no differences between the 2, and only candesartan therapy significantly lowered plasma levels of monocyte chemoattractant protein-1 (p = 0.004 by ANOVA).
authors.affiliation: Department of Cardiology, Vascular Medicine and Atherosclerosis Unit, Gil Heart Center, Gachon Medical School, 1198 Kuwol-dong, Namdong-gu, Incheon 405-760, Korea. kwangk@ghil.com
authors.forename: Kwang Kon
authors.initials: KK
authors.lastname: Koh
authors.forename: Seung Hwan
authors.initials: SH
authors.lastname: Han
authors.forename: Wook-Jin
authors.initials: WJ
authors.lastname: Chung
authors.forename: Jeong Yeal
authors.initials: JY
authors.lastname: Ahn
authors.forename: Dong Kyu
authors.initials: DK
authors.lastname: Jin
authors.forename: Hyung Sik
authors.initials: HS
authors.lastname: Kim
authors.forename: Gi Soo
authors.initials: GS
authors.lastname: Park
authors.forename: Woong Chol
authors.initials: WC
authors.lastname: Kang
authors.forename: Tae Hoon
authors.initials: TH
authors.lastname: Ahn
authors.forename: Eak Kyun
authors.initials: EK
authors.lastname: Shin
mesh_terms: D000804:Angiotensin II; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood*; D001713:Biphenyl Compounds / Q000627:therapeutic use*; D001916:Brachial Artery / Q000502:physiology*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D000077405:Irbesartan; D019808:Losartan / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D013777:Tetrazoles / Q000627:therapeutic use*; D014664:Vasodilation / Q000187:drug effects*
chemical_list: D000959:Antihypertensive Agents; D001562:Benzimidazoles; D015415:Biomarkers; D001713:Biphenyl Compounds; D013777:Tetrazoles; D000804:Angiotensin II; D000077405:Irbesartan; D019808:Losartan; C081643:candesartan